Sifalimumab

Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research[1][2].

Product Specifications

CAS Number

[1006877-41-3]

Product Name Alternative

MEDI-545; MDX 1103

UNSPSC

12352203

Target

IFNAR

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sifalimumab.html

Purity

99.46

Solubility

10 mM in DMSO

Smiles

[Sifalimumab]

Molecular Weight

(144.24 kDa)

References & Citations

[1]Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70 (11) :1905-13.|[2]La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. Drug Deliv Transl Res. 2018 Oct;8 (5) :1345-1354.